Clinical InvestigationExperience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects
Section snippets
MATERIALS AND METHODS
This is a case series collating and reporting retrospective and longitudinal observations on the effects of MMF on clinical, radiological, and pulmonary findings of CTD-ILD in 10 of our clinic patients. Upon decision, to publish these findings, the Louisiana State University institutional review board deemed these findings as “anecdotal communications” not requiring formal approval.
Patients at the Louisiana State University Rheumatology clinics receive a diagnosis of ILD based on evaluation of
RESULTS
The series was comprised of 10 patients (9 women and 1 man) who elected management with MMF; no patients opted for other management strategies. Disease-specific distribution was 4 patients with SSc of whom 2 had established pulmonary hypertension, 3 patients with RA of whom 2 had ILD on initial presentation and were naïve to methotrexate and biologic treatment, 2 patients with PM, and 1 patient with systemic lupus erythematosus (SLE) and Sjögren syndrome (see Table 1). All 4 patients with SSc
DISCUSSION
The natural history of AIR-ILD is not well established, but there is documented evidence in the literature that supports a role for autoimmune phenomena, particularly, in SSc, SLE, PM-DM, and RA, as an important mechanism responsible for alveolar injury leading to pulmonary fibrosis.13 Dedicated efforts to elucidate the natural history of ILD are necessary to provide clinicians and researchers with a platform for which to establish appropriate screening guidelines, develop validated instruments
REFERENCES (37)
- et al.
Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease
Chest
(2006) - et al.
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
Respir Med
(2008) Regulation of PDGF and its receptors in fibrotic diseases
Cytokine Growth Factor Rev
(2004)Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis
J Dermatol Sci
(2008)- et al.
Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats
Biochem Biophys Res Commun
(2006) - et al.
Scleroderma patients with combined pulmonary hypertension and interstitial lung disease
J Rheumatol
(2003) - et al.
Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests
Thorax
(2001) - et al.
Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis
Ann Rheum Dis
(2004) - et al.
Cause of death in 81 autopsied patients with rheumatoid arthritis
J Rheumatol
(1994) - et al.
Pulmonary involvement in patients with early rheumatoid arthritis
Scand J Rheumatol
(2007)
The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis
Rheumatology (Oxford)
Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia
Arthritis Rheum
Severe organ involvement in systemic sclerosis with diffuse scleroderma
Arthritis Rheum
Interstitial lung disease in polymyositis and dermatomyositis
Arthritis Rheum
Cause of death in autopsied RA patients [abstract]
Ryumachi
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) [review]
Am J Respir Crit Care Med
Autoimmunity and interstitial lung disease
Curr Opin Pulm Med
Cited by (76)
Interstitial lung disease and rheumatoid arthritis
2022, Handbook of Systemic Autoimmune DiseasesA 65-year-old Woman With Persistent Dyspnea, Arthritis, and Raynaud's Phenomenon
2021, American Journal of the Medical SciencesTargeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review
2020, Autoimmunity ReviewsCitation Excerpt :ILD early diagnosis and effective treatment are crucial in the management of CTD because lung involvement is burdened by a high degree of morbidity and mortality [22]. Mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus are all reasonable options in CTD-ILD [75–80]; generally, CYC is considered the treatment of choice for more aggressive and evolutive forms of ILD being associated with stabilization of FVC, although its impact on DLCO is less remarkable [81,82]. This outlines the need for novel therapeutic options, particularly for patients with more severe lung involvement.
Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis
2020, Seminars in Arthritis and RheumatismCitation Excerpt :Furthermore, in a recent randomized controlled trial, MMF was shown to be as effective as cyclophosphamide in halting the progression of SSc-associated interstitial lung disease with a better tolerance [15], adding to the prior positive open label experiences [23,24]. Based on these collective observations of beneficial therapeutic effects of MMF for SSc, this drug is frequently used for treating rapidly progressive SSc skin involvement and SSc-associated interstitial lung disease in many centers devoted to SSc medical care [25–32]. Most of the trials that studied MMF therapy for SSc used the drug for an average of 1.5–2 years.
Mycophenolates
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionMyositis in clinical practice—relevance of new antibodies
2018, Best Practice and Research: Clinical Rheumatology
Presented at the American College of Rheumatology 2007 Scientific Meeting in Boston and at the meeting of the Southern Society for Clinical Investigation February 2008 in New Orleans, where this presentation received the Centocor Scholar in Rheumatology Award.